Svetlana P Eckert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8955981/publications.pdf

Version: 2024-02-01

10 papers	154 citations	1163117 8 h-index	10 g-index
10	10	10	165
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs, 2022, 36, 45-59.	5.9	21
2	COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. Vaccines, 2022, 10, 695.	4.4	16
3	Recovery of cognitive function after relapse in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 71-78.	3.0	38
4	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102653.	2.0	13
5	Late onset multiple sclerosis is associated with more severe ventricle expansion. Multiple Sclerosis and Related Disorders, 2020, 46, 102588.	2.0	13
6	Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opinion on Drug Safety, 2020, 19, 1121-1142.	2.4	16
7	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1577-1583.	2.4	4
8	<p>Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives</p> . Patient Related Outcome Measures, 2019, Volume 10, 373-384.	1.2	9
9	Stress-full life events and multiple sclerosis: A population-based incident case-control study. Multiple Sclerosis and Related Disorders, 2018, 26, 168-172.	2.0	15
10	A decline in cognitive function should lead to a change in disease-modifying therapy – Yes. Multiple Sclerosis Journal, 2018, 24, 1681-1682.	3.0	9